Patients with Rheumatoid Arthritis: We’ll Take the Risk

A new study quantifies just how much

18-RHE-1032-Husni-Hero-Image-650x450pxl

Current treatments for rheumatoid arthritis (RA) bring trade-offs for patients: am I okay with a higher risk of cancer if I can live with much less pain? Does a significant increase in function outweigh an increased risk of serious infection? A new study led by M. Elaine Husni, MD, MPH, sought to quantify these questions to help physicians both understand how patients analyze the costs and benefits of RA treatments and engage in shared decision-making.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this discrete choice experiment published in Rheumatology International, researchers asked 510 participants to choose between two hypothetical RA treatments. The treatments had varied levels of efficacy, adverse events and process-related attributes. Using multivariable logistic regression, Dr. Husni, Director of Cleveland Clinic’s Arthritis and Musculoskeletal Treatment Center, and her team assessed the association between these attributes and patients’ decisions and calculated a risk-increase. The results showed that patients with moderate to severe RA will accept increased risk for better physical function and disease control. Just how much?

Adverse effects may discourage some physicians from prescribing the biologic treatments recommended for RA patients with moderate to high disease activity after failure of conventional disease-modifying antirheumatic drugs (DMARDs). “The results of this study show that patients are willing to accept the risk if the benefits are significant, and the increases they’re willing to accept are higher than the actual risk in most cases,” says Dr. Husni. “As physicians, if we understand how patients value treatments, we can improve their acceptance of what we recommend.”

This study is the first in the U.S. to quantify the benefit-risk thresholds in the treatment of RA.

Advertisement

Related Articles

Psoriatic arthritis
Psoriatic Arthritis: Unlocking the Age Factor

Older Psoriasis Patients May Experience Quicker Transition

Mixed connective tissue disease rash
A Little Bit of Everything: Mixed Connective Tissue Disease

Cleveland Clinic’s Rheumatic Lung Disease program treats patients with complex conditions

gout
Finger Nodules: Tip of the Gouty Iceberg

Some patients exhibit marked nodulosis due to undiagnosed tophi

Rheumatology case conference meeting
Weekly Case Conferences Make for Engaged Learning

A century-old medical tradition inspired the weekly complex-case reviews in Rheumatology

psoriasis of the fingernails and psoriatic arthritis on white background
Building a Personalized Medicine Approach to PsA Treatment

Genetic polymorphisms and response to TNFα blockers

yellow nail syndrome
When Edema and Dyspnea Accompany Dyschromic Nails

Patient’s 2-year symptom history leads to an uncommon diagnosis

22-RHE-3091668-Brown-CQD-650×450-jk
Stoking Curiosity and Feeding Knowledge

Adam Brown, MD, shares his passion for solving rheumatologic mysteries

Ad